Partial replacement of d -glucose with d -allose ameliorates peritoneal injury and hyperglycaemia induced by peritoneal dialysis fluid in rats

Abstract

Background:

Peritoneal dialysis (PD) is a crucial dialysis method for treating end-stage kidney disease. However, its use is restricted due to high glucose-induced peritoneal injury and hyperglycaemia, particularly in patients with diabetes mellitus. In this study, we investigated whether partially replacing d-glucose with the rare sugar d-allose could ameliorate peritoneal injury and hyperglycaemia induced by peritoneal dialysis fluid (PDF).

Methods:

Rat peritoneal mesothelial cells (RPMCs) were exposed to a medium containing d-glucose or d-glucose partially replaced with different concentrations of d-allose. Cell viability, oxidative stress and cytokine production were evaluated. Sprague–Dawley (SD) rats were administrated saline, a PDF containing 4% d-glucose (PDF-G4.0%) or a PDF containing 3.6% d-glucose and 0.4% d-allose (PDF-G3.6%/A0.4%) once a day for 4 weeks. Peritoneal injury and PD efficiency were assessed using immuno-histological staining and peritoneal equilibration test, respectively. Blood glucose levels were measured over 120 min following a single injection of saline or PDFs to 24-h fasted SD rats.

Results:

In RPMCs, the partial replacement of d-glucose with d-allose increased cell viability and decreased oxidative stress and cytokine production compared to d-glucose alone. Despite the PDF-G3.6%/A0.4% having a lower d-glucose concentration compared to PDF-G4.0%, there were no significant changes in osmolality. When administered to SD rats, the PDF-G3.6%/A0.4% suppressed the elevation of peritoneal thickness and blood d-glucose levels induced by PDF-G4.0%, without impacting PD efficiency.

Conclusions:

Partial replacement of d-glucose with d-allose ameliorated peritoneal injury and hyperglycaemia induced by high concentration of d-glucose in PDF, indicating that d-allose could be a potential treatment option in PD.

Keywords

peritoneal dialysis rare sugar

Get full access to this article

View all access options for this article.

References

Struijk

. Peritoneal dialysis in western countries. Kidney Dis 2015; 1: 157–164.

Hanafusa

Nakai

Iseki

, et al. Japanese society for dialysis therapy renal data registry – a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl 2015; 5: 15–22.

Hiramatsu

Okumura

Asano

, et al. Quality of life and emotional distress in peritoneal dialysis and hemodialysis patients. Ther Apher Dial 2020; 24: 366–372.

Aroeira

Aguilera

Sánchez-Tomero

, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18: 2004–2013.

Terri

Trionfetti

Montaldo

, et al. Mechanisms of peritoneal fibrosis: focus on immune cells–peritoneal stroma interactions. Front Immunol 2021; 12: 607204.

Zhou

Bajo

Del Peso

, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int 2016; 90: 515–524.

Bonomini

Masola

Procino

, et al. How to improve the biocompatibility of peritoneal dialysis solutions (without jeopardizing the patient’s health). Int J Mol Sci 2021; 22: 7955.

Oba

Mori

Chida

, et al. Glucose and insulin response to peritoneal dialysis fluid in diabetic and nondiabetic peritoneal dialysis patients. Adv Perit Dial 2015; 31: 11–16.

Wijewickrama

Williams

Bain

, et al. Narrative review of glycemic management in people with diabetes on peritoneal dialysis. Kidney Int Rep 2023; 8: 700–714.

10.

Zhang

Jiang

, et al. Enzymatic approaches to rare sugar production. Biotechnol Adv 2017; 35: 267–274.

11.

Izumori

. Izumoring: a strategy for bioproduction of all hexoses. J Biotechnol 2006; 124: 717–722.

12.

Yamada

Iida

Takamine

, et al. Safety evaluation of rare sugar syrup: single-dose oral toxicity in rats, reverse mutation assay, chromosome aberration assay, and acute non-effect level for diarrhea of a single dose in humans. Shokuhin Eiseigaku Zasshi 2015; 56: 211–216.

13.

Hotta

Kaneko

Inuma

, et al. Establishment of a peritoneal mesothelial cell line from a transgenic rat harbouring the temperature-sensitive simian virus 40 large T-antigen gene. Nephrol Dial Transplant 2010; 25: 1825–1832.

14.

Hara

Hamada

Wakabayashi

, et al. Scavenging of reactive oxygen species by astaxanthin inhibits epithelial-mesenchymal transition in high glucose-stimulated mesothelial cells. PLoS One 2017; 12: e0184332.

15.

Vlahu

Aten

de Graaff

, et al. New insights into the effects of chronic kidney failure and dialysate exposure on the peritoneum. Perit Dial Int 2016; 36: 614–622.

16.

Zhou

Sun

, et al. Sulfotanshinone IIA sodium ameliorates glucose peritoneal dialysis solution-induced human peritoneal mesothelial cell injury via suppression of ask1-p38-mediated oxidative stress. Cell Physiol Biochem 2018; 46: 2434–2444.

17.

Ayroldi

Petrillo

Bastianelli

, et al. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells. Cell Death Differ 2015; 22: 118–130.

18.

Cho

Bello

Levin

, et al. Peritoneal dialysis use and practice patterns: an international survey study. Am J Kidney Dis 2021; 77: 315–325.

19.

Brown

Bargman

van Biesen

, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis – position paper for ISPD: 2017 update. Perit Dial Int 2017; 37: 362–374.

20.

Teitelbaum

. Peritoneal dialysis. N Engl J Med 2021; 385: 1786–1795.

21.

Schmitt

Aufricht

. Is there such a thing as biocompatible peritoneal dialysis fluid? Pediatr Nephrol 2017; 32: 1835–1843.

22.

Roumeliotis

Dounousi

Salmas

, et al. Unfavorable effects of peritoneal dialysis solutions on the peritoneal membrane: the role of oxidative stress. Biomolecules 2020; 10: 768.

23.

Liakopoulos

Roumeliotis

Gorny

, et al. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev 2017; 2017: 3494867.

24.

Hou

Zhang

. D-allose alleviates ischemia/reperfusion (I/R) injury in skin flap via MKP-1. Mol Med 2020; 26: 21.

25.

Chen

Chang

Pan

, et al. Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J Am Soc Nephrol 2014; 25: 2847–2858.

26.

Tomino

. Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol 2012; 16: 109–114.

27.

Schaefer

Bartosova

Macher-Goeppinger

, et al. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int 2018; 94: 419–429.

28.

Aroeira

Aguilera

Selgas

, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46: 938–948.

29.

Chen

Zhang

, et al. Recent research on the physiological functions, applications, and biotechnological production of D-allose. Appl Microbiol Biotechnol 2018; 102: 4269–4278.

30.

Ben-David

Hull

Banerjee

. Diabetes mellitus in dialysis and renal transplantation. Ther Adv Endocrinol Metab 2021; 12: 1–16.

31.

Holmes

. Glucotoxicity in peritoneal dialysis – Solutions for the solution! Adv Chronic Kidney Dis 2007; 14: 269–278.

32.

Htay

Johnson

Wiggins

, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2018; 10: CD007554.

33.

Arfeen

Goodship

Kirkwood

, et al. The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution. Clin Nephrol 1990; 33: 192–199.

34.

Menavuvu

Poonperm

Leang

, et al. Efficient biosynthesis of D-allose from D-psicose by cross-linked recombinant L-rhamnose isomerase: separation of product by ethanol crystallization. J Biosci Bioeng 2006; 101: 340–345.

35.

Angyal

. The Lobry de Bruyn-Alberda van Ekenstein transformation and related reactions. In: Stütz

(ed.) Glycoscience. Topics in current chemistry, Vol. 215. Berlin, Heidelberg: Springer, 2001, pp. 1–14.

36.

Bruijn

Kieboom

APG

van Bekkum

. Alkaline degradation of monosaccharides V: kinetics of the alkaline isomerization and degradation of monosaccharides. Rec Trav Chim Pays Bas 1987; 106: 109.

37.

Toyohara

Yamamoto

Tago

. Searching for diagnostic properties of novel fluorine-18-labeled D-allose. Ann Nucl Med 2019; 33: 855–865.

38.

Iga

Nakamichi

Shirai

, et al. Acute and sub-chronic toxicity of D-allose in rats. Biosci Biotechnol Biochem 2010; 74: 1476–1478.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.50 MB